Simethicone for Managing Fullness in Eating Disorder Treatment

Current Evidence on Simethicone

Simethicone is an anti-foaming agent that works by reducing gas bubbles in the digestive tract, and has been extensively studied for improving bowel preparation quality and reducing bloating in irritable bowel syndrome, with a recommended dose of at least 320 mg for effectiveness 1, 2, 3, 4, 5
Meta-analyses have shown that simethicone use, particularly at doses ≥320 mg, is associated with improved bowel preparation quality and fewer bubbles 2, 3, 4

Patients with severe or refractory functional dyspepsia presenting with weight loss and food restriction should be assessed for eating disorders, including avoidant restrictive food intake disorder (ARFID), and early dietitian involvement is recommended to avoid overly restrictive diets 6
Gastrointestinal symptoms, including bloating and fullness, are common in eating disorders but may have different underlying mechanisms than in functional GI disorders 6

Simethicone may help reduce physical discomfort from bloating and fullness that could otherwise trigger anxiety or food avoidance, and could potentially improve compliance with nutritional rehabilitation by reducing uncomfortable fullness sensations 6, 7
Addressing fullness sensations with medication might reinforce avoidance behaviors without addressing underlying psychological factors, and may distract from evidence-based treatments like cognitive behavioral therapy or other psychological interventions 8

Differentiate between normal fullness during refeeding versus pathological bloating that might benefit from symptomatic treatment, and evaluate for comorbid functional gastrointestinal disorders that might respond to simethicone 6, 7
Consider the psychological impact of fullness sensations on treatment adherence, and focus on evidence-based psychological treatments for the eating disorder as the primary intervention 8
If simethicone is empirically trialed, use at least 320 mg for potential effectiveness based on data from other conditions, and monitor for potential reinforcement of symptom preoccupation or avoidance behaviors 4, 5, 8

Dedicated studies on simethicone for fullness specifically in eating disorder populations are needed to examine whether addressing physical symptoms like fullness improves adherence to nutritional rehabilitation, and whether symptomatic treatments for GI symptoms affect long-term eating disorder outcomes 6